Previous 10 | Next 10 |
Calyxt Reports Second Quarter 2021 Financial Results Appointed Michael A. Carr as President and Chief Executive Officer Expanded Commercial Potential of Proprietary Hemp Breeding Platform with Multiple Innovations, including "Pollen-Proof" (Seedless) Hemp and Genome Transfor...
Calyxt to Present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021 PR Newswire ROSEVILLE, Minn. , Aug. 4, 2021 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based biotechnology platform company, today announced that managem...
Calyxt Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PR Newswire ROSEVILLE, Minn. , July 27, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based biotechnology platform company, today announced that, in accordance with the offer...
Calyxt to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time PR Newswire ROSEVILLE, Minn. , July 19, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) will hold a conference call on Thursday, ...
Plant-based biotech Calyxt (CLXT) appointed Michael Carr as President, CEO and board member effective July 27.Carr previously served as vice president of M&A, Strategy, and Innovation at Darling Ingredients Inc., a developer of sustainable natural ingredients and renewable energ...
Calyxt Appoints Michael A. Carr as Chief Executive Officer PR Newswire ROSEVILLE, Minn. , July 15, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based biotechnology platform company, today announced the appointment of Michael A. Carr as Pr...
Calyxt (CLXT) announces further expansion of its hemp breeding platform with the addition of triploid breeding technology to create seedless hemp. Like seedless watermelon, seedless hemp can offer significant advantages in crop management and harvest potential. "Triploid hemp is an important ...
Triploid Breeding Process is Calyxt's Second Announced Advancement and Part of a Comprehensive Approach to Improving Hemp Genetics ROSEVILLE, MN / ACCESSWIRE / July 8, 2021 / Calyxt, Inc. (NASDAQ:CLXT), today announced further expansion of its hemp breeding platform with the additio...
Calyxt is a plant-technology company that develops plant-based innovations and solutions aiming to disrupt a broad group of industries. Calyxt is a leading gene-editor with exclusive access to the parent company's proprietary TALEN technology for use in plants which resulted in the fi...
Cellectis S.A. is an early clinical-stage immuno-oncology biotechnology company specializing in gene-edited T-cells that express chimeric antigen receptors for treating cancer. Cellectis offers a specialization in gene-editing, enabling their CAR-T product candidates to have addi...
News, Short Squeeze, Breakout and More Instantly...
Shares of Calyxt, Inc. (NASDAQ: CLXT) traded at a new 52-week high today and are currently trading at $5.4. So far today, approximately 55,181 shares have been exchanged, as compared to an average 30-day volume of 89,248 shares. Calyxt, Inc., a synthetic biology company, engages in delivering...
Calyxt Announces Stockholder Approval of Merger With Cibus PR Newswire -- Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock -- ROSEVILLE, Minn. , May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announc...
Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire —P roposed merger with Cibus Global Expected to Close in Q2 2023 — —1-for-10 reverse stock split executed— —Current customer...